0.33
+0.0007(+0.22%)
Currency In USD
| Previous Close | 0.33 |
| Open | 0.33 |
| Day High | 0.33 |
| Day Low | 0.33 |
| 52-Week High | 1.56 |
| 52-Week Low | 0.22 |
| Volume | 1.31M |
| Average Volume | 2.85M |
| Market Cap | 29.74M |
| PE | -0.42 |
| EPS | -0.78 |
| Moving Average 50 Days | 0.27 |
| Moving Average 200 Days | 0.74 |
| Change | 0 |
If you invested $1000 in Allakos Inc. (ALLK) since IPO date, it would be worth $10.53 as of July 10, 2025 at a share price of $0.329. Whereas If you bought $1000 worth of Allakos Inc. (ALLK) shares 5 years ago, it would be worth $4.81 as of July 10, 2025 at a share price of $0.329.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share
GlobeNewswire Inc.
Apr 02, 2025 12:00 PM GMT
SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (“Allakos”) (Nasdaq: ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced it h
Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring
GlobeNewswire Inc.
Jan 27, 2025 12:00 PM GMT
– AK006 did not demonstrate therapeutic activity in CSU –– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to host conference call and webcast today at 8:30 am E.T. – SAN
Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results
GlobeNewswire Inc.
Nov 06, 2024 9:02 PM GMT
SAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business updat
Data not available